The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
- 889 Downloads
Obesity and its related complications remain a major threat to public health. Efforts to reduce the prevalence of obesity are of paramount importance in improving population health. Through these efforts, our appreciation of the role of gut-derived hormones in the management of body weight has evolved and manipulation of this system serves as the basis for our most effective obesity interventions.
Purpose of the review
We review current understanding of the enteroendocrine regulation of food intake and body weight, focusing on therapies that have successfully embraced the physiology of this system to enable weight loss.
In addition to the role of gut hormones in the regulation of energy homeostasis, our understanding of the potential influence of enteroendocrine peptides in food reward pathways is evolving. So too is the role of gut derived hormones on energy expenditure.
Gut-derived hormones have the ability to alter feeding behavior. Certain obesity therapies already manipulate this system; however, our evolving understanding of the effects of enteroendocrine signals on hedonic aspects of feeding and energy expenditure may be crucial in identifying future obesity therapies.
KeywordsObesity Endocrine Gut peptides Weight loss
Compliance with Ethical Standards
Conflict of Interest
Audrey Melvin and Neil G. Docherty declare that they have no conflict of interest.
Carel W. le Roux declares personal fees from NovoNordisk, Herbalife and Henry Stewart Talks for education in Obesity; honoraria and travel fees for being an invited speaker at conferences; and money paid to his institution from Science Foundation Ireland, from patents, royalties, for payment for manuscript preparation, and from stocks.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. Adults. N Engl J Med. 1999;341(15).Google Scholar
- 2.WHO. World Health Organisation Global Health Observatory Data; Overweight and Obesity 2014. Available from: http://www.who.int/gho/ncd/risk_factors/overweight/en/.
- 3.Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci. 1998;1(4).Google Scholar
- 14.Cummings DE, Purnell JQ, Scott Frayo R, Schmidova K, Wisse BE, Weigle DS. A Preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50.Google Scholar
- 15.Masamitsu Nakazato NM, Yukari Date, Masayasu Kojima, Hisayuki Matsuo, Kenji Kangawa & Shigeru Matsukura. A role for ghrelin in the central regulation of feeding. Nature. 2001;409.Google Scholar
- 21.Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;5.Google Scholar
- 23.Cummings DE, Weigle DS, Scott Frayo R, Breen PA, Ma MK, Dellinger P, et al. Plasma Ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21).Google Scholar
- 31.Grandt D, Dahms P, Schimiczek M, Eysselein VE, Reeve Jr JR, Mentlein R. [Proteolytic processing by dipeptidyl aminopeptidase IV generates receptor selectivity for peptide YY (PYY)]. Med Klin (Munich). 1993;88(3):143–5.Google Scholar
- 39.Orskov C, Bersani M, Johnsen AH, Hajrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem. 1989;264(22).Google Scholar
- 42.Mentlein R, B. G, W.E. S. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-likepeptide-l(7–36)amide, peptidehistidinemethionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:826–835).Google Scholar
- 48.McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7—36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. 1997.Google Scholar
- 56.Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1–38). J Biol Chem. 2003;278(25):22418–23.CrossRefPubMedGoogle Scholar
- 61.Parkinson JR, Chaudhri OB, Kuo YT, Field BC, Herlihy AH, Dhillo WS, et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage. 2009;44(3):1022–31.CrossRefPubMedGoogle Scholar
- 66.Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, et al. The inhibitory effects of peripheral administration of peptide YY(3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005;1044(1):127–31.CrossRefPubMedGoogle Scholar
- 73.•Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21(2):159–65. This paper reports on increased energy expenditure mediated through intestinal FXR activation. CrossRefPubMedPubMedCentralGoogle Scholar
- 84.Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52.CrossRefPubMedGoogle Scholar
- 87.Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247(3):401–7.CrossRefPubMedGoogle Scholar
- 88.•Scholtz S, Miras AD, Chhina N, Prechtl CG, Sleeth ML, Daud NM, et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut. 2014;63(6):891–902. This paper demonstrates decreased neural food reward pathways following RYGB surgery.Google Scholar
- 89.•Goldstone AP, Miras AD, Scholtz S, Jackson S, Neff KJ, Penicaud L, et al. Link between increased satiety gut hormones and reduced food reward after gastric bypass surgery for obesity. J Clin Endocrinol Metab. 2016;101(2):599–609. This paper demonstrates decreased activity in neural food reward pathways following RYGB surgery.Google Scholar
- 96.Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.CrossRefPubMedPubMedCentralGoogle Scholar
- 99.Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59(5):945–65.CrossRefGoogle Scholar